Pyxis Oncology Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing next-generation cancer therapies. By harnessing the power of antibody-drug conjugates (ADCs) and immuno-oncology approaches, the company aims to create targeted treatments that improve outcomes for cancer patients. With a commitment to scientific innovation and precision medicine, Pyxis Oncology is advancing a pipeline of novel therapies designed to enhance the effectiveness and safety of cancer treatments. As it progresses through clinical trials, the company remains dedicated to transforming oncology care with cutting-edge biopharmaceutical solutions.
Latest shares articles
Trading the Nasdaq 100 as Tariffs Take Effect
Not far off recovering from last Thursday’s losses buoyed by big gains from a few of Big Tech, and in sentiment still a story of majority buy bias.
06:35, 7 August 2025
Capital.com donates €50,000 to the Cyprus Red Cross Society to support wildfire relief efforts
Capital.com donates €50,000 to the Cyprus Red Cross Society to aid families affected by wildfires, reinforcing its commitment to community support.
09:49, 5 August 2025
Trading the Dow 30 after the disappointing Non-Farm Payrolls
Technical overview shifts in the key index following the pullback late last week made worse by a deteriorating labor market, while CoT speculators shift to net sell for the first time in months.
07:55, 4 August 2025
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
14:48, 31 July 2025
Ratings and Reviews
Ratings and Reviews
